Northwestern Mutual Wealth Management
RVNC

Northwestern Mutual Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20
Closed -$61 – 4015
2024
Q4 		$61 Sell
20
-1,680
-99% -$7.32K ﹤0.01% 3510
2024
Q3 		$8.82K Sell
1,700
-1,602
-49% -$7.96K ﹤0.01% 2726
2024
Q2 		$8.49K Buy
+3,302
New +$11.3K ﹤0.01% 2702
2024
Q1 		– Sell
-4,400
Closed -$38.7K – 3856
2023
Q4 		$38.7K Buy
+4,400
New +$36K ﹤0.01% 2162
2023
Q3 		– Sell
-50
Closed -$1.27K – 3572
2023
Q2 		$1.27K Buy
50
+45
+900% +$1.4K ﹤0.01% 3055
2023
Q1 		$161 Buy
+5
New +$156 ﹤0.01% 3207
2021
Q1 		– Sell
-71
Closed -$2K – 2993
2020
Q4 		$2K Buy
+71
New +$1.84K ﹤0.01% 2558

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northwestern Mutual Wealth Management's RVNC Position: Q1 2025 in Review

Northwestern Mutual Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 20 shares — an estimated $61 sold.

Northwestern Mutual Wealth Management first reported a position in RVNC in Q4 2020 and held it in 7 quarters. The position peaked at $38.7K in Q4 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Northwestern Mutual Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 20 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $61.
  • Northwestern Mutual Wealth Management first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 7 quarters.
  • Northwestern Mutual Wealth Management's Revance Therapeutics, Inc. position peaked at $38.7K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2025, filed 14 May 2025.